Table 2 The probit analyses based on subgroups between biological equivalence dose and 6-month local control
From: Dose-effect relationship of linear accelerator based stereotactic radiotherapy for brain metastases
Parameter | Nominal BED10 (GyBED10) | Peripheral BED10 (GyBED10) | Central BED10 (GyBED10) | Average BED10 (GyBED10) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
s (p) | ED90 (95% CI) | P | s (p) | ED90 (95% CI) | P | s (p) | ED90 (95% CI) | P | s (p) | ED90 (95% CI) | P | |
Country | ||||||||||||
Japan | 5 (212) | 64.8 (-, -) | 0.051 | 5 (212) | 60.7 (46.9, 71.0) | 0.015 | 4 (199) | 73.0 (61.8, 90.6) | 0.016 | 4 (199) | 66.1 (59.5, 79.0) | 0.019 |
Italy | 5 (432) | 50.0 (49.6, 50.4) | < 0.0001 | 5 (432) | 50.0 (49.6, 50.4) | < 0.0001 | 5 (432) | 57.2 (54.4, 60.6) | < 0.0001 | 5 (432) | 54.3 (52.6, 55.7) | < 0.0001 |
Treatment era | ||||||||||||
Before 2010 | 10 (524) | 56.9 (-, -) | 0.217 | 10 (524) | 55.0 (-, -) | 0.192 | 8 (366) | 66.3 (-, -) | 0.053 | 8 (366) | 55.6 (-, -) | 0.126 |
After 2005 | 11 (642) | 45.2 (-80.3, 50.8) | 0.040 | 11 (642) | 42.7 (-, -) | 0.121 | 10 (629) | 53.6 (-415.8, 64.2) | 0.045 | 10 (629) | 52.9 (33.6, 57.3) | 0.013 |
Proportion of male patients | ||||||||||||
≤ 50% | 11 (750) | 52.0 (32.5, 59.5) | 0.023 | 11 (750) | 50.9 (-, -) | 0.063 | 9 (592) | 63.8 (58.2, 68.3) | < 0.0001 | 9 (592) | 56.8 (52.5, 59.9) | 0.000 |
> 50% | 8 (379) | 85.8 (-, -) | 0.596 | 8 (379) | -2.4 (-, -) | 0.796 | 7 (366) | 76.9 (-, -) | 0.099 | 7 (366) | 75.2 (-, -) | 0.470 |
Median age | ||||||||||||
≥ 62 | 10 (517) | 32.7 (-589.1, 46.1) | 0.042 | 10 (517) | 28.0 (-, -) | 0.080 | 9 (497) | -79.0 (-, -) | 0.284 | 9 (497) | -15.2 (-, -) | 0.236 |
< 62 | 9 (615) | 51.3 (-, -) | 0.488 | 9 (615) | 51.6 (-, -) | 0.160 | 8 (602) | 67.2 (62.6, 72.2) | < 0.0001 | 8 (602) | 59.3 (55.7, 63.3) | 0.001 |
Median tumour diameter * | ||||||||||||
< 20 mm | 8 (530) | 73.6 (-, -) | 0.072 | 8 (530) | 69.8 (58.6, 452.5) | 0.042 | 6 (379) | 87.9 (80.1, 104.1) | < 0.0001 | 6 (379) | 66.7 (61.3, 76.3) | < 0.0001 |
≥ 20 mm | 8 (608) | 49.3 (46.0, 50.1) | 0.007 | 8 (608) | 43.9 (-, -) | 0.122 | 8 (588) | 77.1 (73.2, 86.2) | 0.001** | 8 (588) | 63.9, (61.9, 68.6) | 0.001** |
PTV margin | ||||||||||||
≤ 2 mm | 13 (995) | 71.2 (-, -) | 0.242 | 13 (995) | 70.9 (-, -) | 0.331 | 11 (844) | 34.5 (-, -) | 0.366 | 11 (844) | 26.4 (-, -) | 0.455 |
> 2 mm | 5 (178) | 48.2 (-, -) | 0.993 | 5 (178) | 48.2 (-, -) | 0.993 | 4 (158) | 51.6 (-, -) | 0.993 | 4 (158) | 49.8 (-, -) | 0.992 |
Fractions | ||||||||||||
1 | 11 (806) | 41.1 (-, -) | 0.195 | 11 (806) | 41.1 (-, -) | 0.195 | 9 (655) | 47.4 (-, -) | 0.110 | 9 (655) | 45.9 (-, -) | 0.065 |
2–5 | 9 (459) | 47.2 (-, -) | 0.347 | 9 (459) | 48.2 (-, -) | 0.151 | 8 (439) | 59.3 (54.0, 64.9) | 0.001 | 8 (439) | 55.3 (52.3, 58.5) | 0.001 |
Treatment technology | ||||||||||||
CSC | 4 (208) | 47.0 (-, -) | 0.102 | 4 (208) | 47.0 (-, -) | 0.102 | 4 (208) | 65.5 (-, -) | 0.334 | 4 (208) | 55.9 (-, -) | 0.269 |
MLC | 8 (603) | -11.7 (-, -) | 0.616 | 8 (603) | -240.8 (-, -) | 0.910 | 8 (603) | 125.7 (-, -) | 0.176 | 8 (603) | 117.8 (-, -) | 0.355 |
Noncoplanar | 7 (785) | 77.9 (-, -) | 0.523 | 7 (785) | 77.9 (-, -) | 0.523 | 6 (647) | -3145.8 (-, -) | 0.989 | 6 (647) | -38.9 (-, -) | 0.756 |
CNS | 5 | 3 | 7 | 7 | ||||||||